A phase 2 clinical trial has found that combining a novel compound called alisertib with chemotherapy has anti-tumour activity in children with high-risk, relapsed neuroblastoma.
The New Approaches to Neuroblastoma Therapy (NANT) consortium study was led by Araz Marachelian, MD, MS, of the Children's Centre for Cancer and Blood Diseases at Children's Hospital Los Angeles and Steven G. DuBois, MD, of the Dana-Farber Cancer Institute.
Results were recently published online in the journal Clinical Cancer Research.
In the multicentre trial, alisertib was combined with two common chemotherapy agents: irinotecan and temozolomide.
Alisertib is an experimental compound that targets and inhibits a particular enzyme, called an Aurora A kinase, which neuroblastoma tumours often use to grow.
Neuroblastoma is the second most common solid tumour in children (after brain tumours).
The cancer arises in immature nerve cells called neuroblasts, and it typically affects children ages 5 or younger.
Nearly half of patients are diagnosed with high-risk, metastatic disease, which has a 50 percent mortality rate.
The NANT study, a follow-up to an earlier phase 1 trial, evaluated the combination therapy in a group of 20 patients with high-risk neuroblastoma that had relapsed or had not responded to standard treatment.
Of those patients, 21 percent had an objective response rate, showing significant improvement in all cancer sites in their body.
One-year progression-free survival was 34 percent.
"For relapsed neuroblastoma, those are good results," says Marachelian, clinical director of the Neuroblastoma Program at CHLA and medical director of the NANT consortium, which is headquartered at CHLA. "This study shows that inhibiting the aurora kinase pathway has a potential role in treating advanced neuroblastoma, and it helped us understand more about the anti-tumour activity and toxicity of this combination."
Researchers had been hoping that the therapy would be particularly effective for children whose tumours have a gene called MYCN that is over-expressed, or "amplified."
Aurora kinases stabilise a key protein in MYCN, so researchers had aimed to disrupt that protein with alisertib, and potentially increase treatment effectiveness.
MYCN amplification occurs in about 25 percent of neuroblastoma patients, and it is associated with more aggressive disease and poorer outcomes.
"What we found, though, was that the treatment actually worked better for kids whose tumours did not have MYCN amplification," says Marachelian, an assistant professor of Paediatrics at the Keck School of Medicine at the University of Southern California. "Both groups could still benefit from this therapy, but we clearly have more work to do in targeting this pathway."
In addition, the trial was the first to evaluate a liquid form of alisertib in children.
A separate group of 12 patients in the study received this oral solution as part of the combination therapy, instead of a tablet form of the drug.
"Neuroblastoma affects toddlers and young children, and many of these kids aren't able to swallow pills," she adds. "An oral solution expands the number of patients able to receive this treatment, and the study enabled us to identify a dosing regimen."
Researchers plan to continue to target the aurora kinase pathway in neuroblastoma studies.
NANT, a group of 14 North American paediatric cancer centres, is the only consortium in the world solely dedicated to developing novel treatments and biomarkers through early clinical trials for neuroblastoma.
Source: Children's Hospital Los Angeles
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.